Redhill Biopharma LTD F-1 registration statements

RedHill Biopharma filed an amended registration statement for the resale of up to 6.47 million ADSs by YA II PN, LTD., tied to a $25 million standby equity purchase agreement, amidst a preliminary revenue decline.

RedHill Biopharma Ltd. filed an F-1 registration statement for the resale of up to 6.47 million American Depositary Shares by YA II PN, LTD., potentially raising up to $25 million, while also announcing a major legal victory and Nasdaq compliance.

RedHill Biopharma Ltd. has filed an F-1 registration statement for the resale of up to 5.6 million American Depositary Shares by Alumni Capital LP, stemming from a new $10 million equity line of credit, as the company grapples with a significant stockholders' deficit and Nasdaq listing non-compliance.

RedHill Biopharma is registering for the resale of up to 10.6 million American Depositary Shares (ADSs) by selling shareholders, following a registered direct offering and concurrent private placement.